Article
Oncology
Miryam Yusufov, Margo Nathan, Aleta Wiley, Julia Russell, Ann Partridge, Hadine Joffe
Summary: Pre-existing psychological and menopause symptoms can predict non-adherence to oral anti-estrogen therapies in early-stage hormone receptor-positive breast cancer. These symptoms can help identify patients at risk for non-adherence and guide interventions for psychological and symptom management.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Endocrinology & Metabolism
Antonio Galvano, Valerio Gristina, Dalila Scaturro, Tancredi Didier Bazan Russo, Sofia Tomasello, Fabio Vitagliani, Federica Carita, Maria La Mantia, Fabio Fulfaro, Viviana Bazan, Giulia Letizia Mauro, Antonio Russo
Summary: This study compared the impact of alendronate and denosumab on secondary osteoporosis prevention and pain control in early breast cancer patients. The results showed that both treatments significantly improved lumbar spine bone density, with alendronate also significantly impacting pain control.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Ida Dragvoll, Anna M. M. Bofin, Havard Soiland, Gunnar Taraldsen, Monica Jernberg Engstrom
Summary: Adherence to antihormonal therapy for breast cancer is suboptimal, with better adherence seen in patients with extremes of age and with metastasis to axillary lymph nodes.
Review
Oncology
Li Huifang, Gao Jie, Feng Yi
Summary: Aromatase inhibitors are the most commonly used endocrine therapy for breast cancer patients, but they often cause adverse reactions such as muscle and joint pain, fatigue, anxiety, depression, and sleep disturbances. The rapid decline of hormones leads to inflammation and bone loss. Therefore, studying poor adherence from the perspective of neuro-immuno-endocrine is of great significance for clinical intervention.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Lindsay J. Collin, Deirdre P. Cronin-Fenton, Thomas P. Ahern, Michael Goodman, Lauren E. McCullough, Lance A. Waller, Anders Kjaersgaard, Per Damkier, Peer M. Christiansen, Bent Ejlertsen, Maj-Britt Jensen, Henrik Toft Sorensen, Timothy L. Lash
Summary: This study evaluated the association between early discontinuation of endocrine therapy and breast cancer recurrence in premenopausal women. The results showed a higher rate of recurrence in women who discontinued endocrine therapy compared to those who completed the recommended treatment. These findings emphasize the importance of clinical follow-up and behavioral interventions to support the persistence of adjuvant endocrine therapy in preventing breast cancer recurrence.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Steven Davies, Ioannis A. Voutsadakis
Summary: This study found that adjuvant chemotherapy is associated with better adherence to hormonal therapy in early ER-positive breast cancer patients, while patients with psychiatric co-morbidities are more likely to be non-adherent to hormonal therapy.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Article
Medicine, General & Internal
Elie Rassy, Aurelie Bardet, Omar Bougacha, Laurene Gantzer, Beranger Lekens, Suzette Delaloge, Fabrice Andre, Stefan Michiels, Barbara Pistilli
Summary: Suboptimal adherence to endocrine therapy (ET) significantly affects survival outcomes among patients with hormone-receptor-positive breast cancer. This study examines the association between potential drug-drug interactions (PDDI) with tamoxifen or aromatase inhibitor and adherence to ET in breast cancer patients.
Article
Cell Biology
Deborah Molehin, Fahmida Rasha, Rakhshanda Layeequr Rahman, Kevin Pruitt
Summary: The regulation of aromatase, an enzyme involved in estrogen biosynthesis, is associated with growth factor signaling and immune response modulation. Aromatase inhibitors (AIs) are used in treating hormone-dependent cancers but the increase in AI-resistance calls for new targeted therapies. Tumor and stromal-derived growth factors and immune cell modulators play key roles in regulating aromatase activity.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Havard Soiland, Jurgen Geisler, Tone Hoel Lende, Per Eystein Lonning, Jorn Sagen, Gunnar Mellgren, Bjorg Almas
Summary: This study developed a liquid chromatography-tandem mass spectrometry (MS/MS) method for simultaneous measurement of serum levels of third-generation aromatase inhibitors (AIs) and ultra-low levels of estrogens. The method is highly valuable for studying drug efficacy and compliance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Multidisciplinary Sciences
Kaiyue Wang, Lu Shen, Wei Tian, Suzhan Zhang
Summary: This retrospective cohort study aimed to investigate the effect of endocrine therapy on serum lipids in premenopausal women with early breast cancer. The results showed that different types of endocrine treatments had varying effects on blood lipids, with some treatments improving lipid levels but also carrying certain risks.
SCIENTIFIC REPORTS
(2022)
Review
Chemistry, Medicinal
Ankita Sood, Damanpreet Kaur Lang, Rajwinder Kaur, Balraj Saini, Sandeep Arora
Summary: Treatment for breast cancer remains challenging, with aromatase inhibitors showing significantly improved efficacy and safety compared to other drugs.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2021)
Review
Endocrinology & Metabolism
Aya Bassatne, Abir Bou Khalil, Marlene Chakhtoura, Asma Arabi, Catherine Van Poznak, Ghada El-Hajj Fuleihan
Summary: This study suggests a protective effect of antiresorptive drugs on bone mineral density and bone turnover markers in postmenopausal women with non-metastatic breast cancer on aromatase inhibitors (AIs), but the data on fracture risk reduction is still unclear.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Oncology
Oluchi Oke, Jiangong Niu, Mariana Chavez-MacGregor, Hui Zhao, Sharon H. Giordano
Summary: The study found a high rate of tamoxifen discontinuation among male breast cancer patients, with even among those continuing treatment a substantial number of non-adherent patients.
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Milana A. Bergamino, Elena Lopez-Knowles, Gabriele Morani, Holly Tovey, Lucy Kilburn, Eugene F. Schuster, Anastasia Alataki, Margaret Hills, Hui Xiao, Chris Holcombe, Anthony Skene, John F. Robertson, Ian E. Smith, Judith M. Bliss, Mitch Dowsett, Maggie C. U. Cheang
Summary: This study aimed to identify biomarkers for the response of ER+/HER2+ breast cancers to AI treatment. The results showed that HER2-E is a standardized biomarker associated with poor response to AI and worse prognosis in ER+/HER2+ breast cancers. HRD, TP53 mutational score, and immune-tumor tolerance are predictive biomarkers for poor response to AI. Additionally, new molecular subtypes identify non-HER2-E tumors that do not respond to AI and have an increased risk of relapse.
